ArticleEuropean stroke journal2026
Primary versus elective percutaneous transluminal angioplasty with stenting for symptomatic intracranial atherosclerotic stenosis: a 18-centre retrospective cohort study using the pEGASUS-HPC stent.
Article in European stroke journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo describe the safety and effectiveness of percutaneous transluminal angioplasty with pEGASUS-HPC stenting (PTAS) for symptomatic intracranial atherosclerotic stenosis (sICAS) and compare primary versus elective use. PATIENTS AND
methodsWe retrospectively included consecutive adults with sICAS ≥50% treated with pEGASUS-HPC PTAS at 18 neurovascular centres (May 2021-February 2025). Primary PTAS was defined as treatment during non-large-vessel-occlusion acute ischaemic stroke (AIS); Elective PTAS was performed at least 7 days after the qualifying ischaemic presentation for recurrent symptoms or haemodynamic compromise despite intensive medical therapy. Outcomes included technical success (post-treatment stenosis ≤50% without intraprocedural complications), in-hospital major complications (intracerebral haemorrhage, AIS or death), restenosis and functional status, measured by the modified Rankin Scale (mRS) at last follow-up.
resultsAmong 141 patients (Primary 71; Elective 70), median post-treatment stenosis was 23.0%; technical success was 94.3% (90.1% vs 98.6%; P = .063). In-hospital major complications occurred in 7.1% (12.7% Primary vs 1.4% Elective; P = .017), driven by intraprocedural in-stent thrombosis (9.9% vs 0%; P = .013). At last follow-up (median 9 months), restenosis ≥50% was observed in 14.3% (7.8% vs 19.7%; P = .10) and mRS <3 in 84.7% (82.1% vs 87.1%; P = .61). New diffusion-weighted imaging lesions were seen in 39.2% of 79 patients with early MRI, without group differences. DISCUSSION: In this multicentre cohort, pEGASUS-HPC PTAS provided substantial luminal gain, moderate restenosis and good mid-term functional outcomes overall. Elective use in medically refractory sICAS was associated with very low major complication rates, whereas primary use during AIS carried significantly higher thrombotic and haemorrhagic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.